TriSalus Life Sciences

TLSI

Market cap $205M

LOS ANGELES--(BUSINESS WIRE)---- $TLSI--TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ: TLSI) concerning potential violations of the federal securities laws. TLSI reported Q1 2026 revenue of $8.9 million.

TriSalus Life Sciences Inc. reaffirmed $60-$62 million revenue guidance on March 5, 2026. Months later, the company cut that outlook to $54-$57 million after missing Q1 estimates.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TRISALUS LIFE SCIENCES INC. (TLSI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TRISALUS LIFE SCIENCES INC. (TLSI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your.

New York, New York--(Newsfile Corp. - May 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:TLSI) concerning potential violations of the federal securities laws. TLSI reported Q1 2026 revenue of $8.9 million.

NEW YORK--(BUSINESS WIRE)--Shareholders who held TriSalus Life Sciences Inc. (TLSI) stock lost money after the company cut its full-year 2026 revenue guidance to $54 million-$57 million, down from the $60 million-$62 million range reaffirmed approximately two months earlier on March 5, 2026. Those who purchased TLSI shares and suffered losses are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by t.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TRISALUS LIFE SCIENCES INC. (TLSI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 12, 2026, TriSalus reported first quarter.

New York, New York--(Newsfile Corp. - May 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ: TLSI) concerning potential violations of the federal securities laws. TLSI reported Q1 2026 revenue of $8.9 million.